Fulcrum Therapeutics
Price & Volume
Stats
See more52W Range | $2.31-$15.73 |
Market Cap | $763.9M |
Shares Short | 2M |
Financials
See moreRevenue (12 Mos) | $0 |
Revenue Growth (YoY) | -100% |
Gross Profit (12 Mos) | -$52.4M |
Diluted EPS | -$1.14 |
News
See moreYahoo Finance • 18 days ago
Fulcrum Therapeutics announces pricing of upsized $175M public offering of common stock, pre-funded warrants
Yahoo Finance • 20 days ago
Fulcrum Therapeutics Announces Proposed $150.0 Million Public Offering of Common Stock
Yahoo Finance • 22 days ago
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Yahoo Finance • 23 days ago
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
About
CEO | Mr. Alexander C. Sapir |
Address | 26 Landsdowne Street, Cambridge, MA, United States, 02139 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 45 |
